Evidence map›Paper›PMID 38295318›Full record

ArticleJCO precision oncology2024

Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights.

Shivani Handa, Kyle A Farina, Michelle Becker, Brianna Kelly, Ashley Yu, Jonathan Feld, Douglas Tremblay, Bridget K Marcellino, Christian Salib, John Mascarenhas and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shivani HandaTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-1932-6209
Kyle A FarinaDepartment of Pharmacy Practice, The Mount Sinai Hospital, New York, NY.
Michelle BeckerTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0009-0005-0081-448X
Brianna KellyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Ashley YuTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0009-0008-6876-9998
Jonathan FeldTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Douglas TremblayTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Bridget K MarcellinoTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Christian SalibDepartment of Pathology, Molecular & Cell-Based Medicine, Icahn School of Medicine, The Mount Sinai Hospital, New York, NY.ORCID 0000-0001-5466-6949
John MascarenhasTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-8400-0483
Alan H ShihTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-4618-9673

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the first case of pacritinib-withdrawal syndrome with in vitro elucidation of underlying mechanisms.

Indexed as

Primary MyelofibrosisBridged-Ring CompoundsHumansJanus Kinase 2PyrimidinesBridged-Ring CompoundsJAK2 protein, humanJanus Kinase 2Pyrimidines

Identifiers

PMID38295318
PMCPMC10843369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.